Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in US

Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in US

311611

Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in US

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, safety, and efficacy required for approval in the U.S. Because of patent infringement allegations filed against the company, however, full approval — which allows for commercial use — may not be granted until at least late October,…

You must be logged in to read/download the full post.